Targeting drug-resistant ALK mutations, the third-generation ALK tyrosine kinase inhibitor loratinib exerted unprecedented preclinical activity as a single agent in a xenograft model of neuroblastoma patients with three hotspot mutations (25). Here, ALK is linked to neuroblastoma.